Access FR version Appel aux parties intéressées
With the rapidly emerging field of precision medicine, more complex, expensive, and promising genetic and genomic tests are being developed to identify biomarkers that can help inform treatment and care — currently, most prominently in the field of cancer. Health decision-makers across jurisdictions in Canada make decisions about implementing tests for various biomarkers that may inform cancer prevention, diagnosis, treatment, and prognosis; however, approaches to evaluation and decision-making are variable and inconsistent, which has been observed to introduce inequities in availability and timely access to biomarker testing and precision medicine technologies.
Canada’s Drug Agency (CDA-AMC) aims to address these disparities, at least in part, by convening a time-limited advisory panel with the key objectives to:
- develop a consensus-based framework to inform adoption or funding decisions on genetic and genomic biomarker testing in cancer care
- identify best practices and gaps across jurisdictions
- provide actionable considerations to facilitate implementation of the framework within jurisdictions
- engage contributing parties from various jurisdictions to build consensus and collaboration.
Interested parties will be engaged to add valuable input from diverse perspectives.
CDA-AMC invites people with personal or professional experience with genetic and genomic testing for biomarkers in cancer care in Canada to connect with us to be informed of this project as it continues. This may include patients, families, and caregivers; patient group representatives; clinical groups, associations, or representatives; industry partners; clinicians; geneticists; pathologists; health system payers; and other health system decision-makers.
If you have an interest in this topic and wish to be informed of any updates or opportunities to be involved, such as providing feedback on draft documents or attending a webinar, please complete the following form .